EE426 Budget Impact Analysis of Atezolizumab in 1ST Line Treatment for Patients With PD-L1 High Metastatic NSCLC From a French Payor Perspective
Abstract
Authors
K Benyounes M Delzard K Le Lay F Bianic C Bougeard
K Benyounes M Delzard K Le Lay F Bianic C Bougeard
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now